AVI 7288

Drug Profile

AVI 7288

Alternative Names: AVI-7288

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AVI BioPharma
  • Developer Sarepta Therapeutics; United States Department of Defense
  • Class Antisense oligonucleotides; Antivirals
  • Mechanism of Action RNA interference; Viral RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Marburg virus disease
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Marburg virus disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Marburg virus disease(In volunteers) in USA (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Marburg virus disease in USA (IM)
  • 10 Feb 2014 Adverse events data from a phase I, multiple ascending dose (MAD) trial in Marburg virus disease (in volunteers) released by Sarepta Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top